Request a Quote
Skip to main content

Post-viral cerebellar ataxia: 5 to 8 week warning window

Post-viral cerebellar ataxia can appear weeks after encephalitis and still respond to immunotherapy if it is recognized early. In two reported cases, gait instability, limb dysmetria, and dysarthria emerged 5 to 8 weeks after acute human herpesvirus encephalitis had resolved. Both patients had received acyclovir during the acute phase, and both carried anti-neurochondrin IgG in serum and cerebrospinal fluid at a titer of 1:100. Neither brain imaging nor standard cerebellar antibody panels explained the new symptoms. Combined steroid pulses and intravenous immunoglobulin restored independent walking within 3 months. The cases argue for a targeted antibody test when cerebellar signs return after an apparently successful antiviral course.

Why post-viral cerebellar ataxia is easy to miss

Acute viral encephalitis is a dramatic illness. Patients arrive with fever, headache, vomiting, altered consciousness, or focal deficits. Antiviral therapy starts, the virus is identified, and the acute syndrome resolves. Everyone assumes the story is over. Then, five to eight weeks later, the patient returns with a different problem: the gait is wide and unsteady, speech is slurred, and the hands overshoot when reaching for an object.

That interval is the diagnostic trap. The new syndrome is an immune response that surfaced after the infectious trigger cleared, so a relapse of the infection is the wrong working diagnosis. In the reported cohort, 54 patients met consensus criteria for primary autoimmune cerebellar ataxia. Only two had both a documented preceding herpesvirus encephalitis and paired serum and cerebrospinal fluid positivity for anti-neurochondrin IgG. The remaining 52 were negative for that antibody. Because the center did not screen every encephalitis survivor, the true incidence of this complication cannot be calculated from the data. What the cases do show is a pattern worth recognizing: a delayed, subacute pancerebellar syndrome with a normal brain MRI and a negative routine antibody panel.

The distinction changes treatment. Continuing or restarting acyclovir leaves the antibody-mediated process untouched; immunosuppression addresses it. Misreading the second illness as viral relapse delays the intervention that appears to have driven recovery in these two patients.

How the cases were identified and tested

Element

What was done

What it yielded

Cohort

54 consecutive patients meeting 2020 consensus criteria for primary autoimmune cerebellar ataxia

2 patients with both prior herpesvirus encephalitis and paired anti-neurochondrin IgG positivity

Pathogen detection

Metagenomic next-generation sequencing on cerebrospinal fluid and peripheral blood

Human herpesvirus 4 in one case and human herpesvirus 6 in the other

Antibody testing

Combined cell-based assay, tissue-based assay, and dot immunobinding on serum and cerebrospinal fluid

Neurochondrin IgG titer of 1:100 in both compartments for both patients

Imaging

Brain MRI, whole-body fluorodeoxyglucose positron emission tomography with CT

No cerebellar lesion or atrophy; no occult malignancy

Literature comparison

Structured search of published anti-neurochondrin ataxia cases through December 2025

19 cases available for descriptive pooled analysis

The antibody workup used serial twofold dilution until specific immunofluorescence disappeared. Other cerebellar antigens were tested in the same panel: GAD65, Homer-3, ATP1A3, ARHGAP26, ITPR-1, septin-5, and the common limbic encephalitis antigens. All were negative in both patients. The negative panel is as informative as the positive one. Stopping at a standard cerebellar antibody screen leaves the clinician without an explanation and often without the neurochondrin assay result.

The literature review applied a case-report appraisal checklist and followed reporting principles for descriptive synthesis. It assembled 19 anti-neurochondrin ataxia cases, including the two new ones. With 19 cases, percentages from this group describe reported cases only and cannot serve as population estimates.

What post-viral cerebellar ataxia looked like in the two cases

The first patient was 63 years old. At encephalitis presentation, the opening pressure was 220 millimeters of water, the cerebrospinal fluid white cell count was 62 x 10^6 per liter, and the protein concentration was 506.2 milligrams per deciliter. Metagenomic sequencing detected human herpesvirus 4 DNA. The patient received 2 weeks of intravenous aciclovir followed by 1 week of oral acyclovir. Acute symptoms resolved completely by discharge.

Six weeks later, persistent dizziness, a broad-based unstable gait, slurred low-volume speech, and bilateral limb dysmetria appeared. The Romberg sign was positive. Repeat imaging showed no cerebellar lesion, no atrophy, no meningeal enhancement, and no new parenchymal signal change. Repeat lumbar puncture showed an opening pressure of 120 millimeters of water, 2 white cells x 10^6 per liter, and protein of 383.8 milligrams per deciliter. Oligoclonal bands were absent and the IgG index was normal. Tissue-based assay using cerebrospinal fluid produced diffuse granular fluorescence across cerebellum, cortex, hippocampus, and thalamus. Cell-based assay confirmed neurochondrin IgG in both serum and cerebrospinal fluid at 1:100.

The second patient was 54 years old and presented with fever, severe headache, hypersomnia, and impaired calculation. Opening pressure was 210 millimeters of water and cerebrospinal fluid white cells were 58 x 10^6 per liter. After recovery from human herpesvirus 6 encephalitis, a subacute cerebellar syndrome emerged. The same paired antibody pattern was found. Both patients eventually received the same immunotherapy approach and both recovered independent ambulation.

Clinical feature

Patient 1

Patient 2

Age at encephalitis

63 years

54 years

Virus detected

Human herpesvirus 4

Human herpesvirus 6

Latency to cerebellar onset

6 weeks after discharge

Within the reported 5 to 8 week interval

Cerebrospinal fluid white cells at encephalitis

62 x 10^6 per liter

58 x 10^6 per liter

Cerebrospinal fluid protein at encephalitis

506.2 milligrams per deciliter

Not stated in the abstract level data

Serum and cerebrospinal fluid neurochondrin IgG

1:100 in both

1:100 in both

Brain MRI during ataxia

No lesion or atrophy

No lesion or atrophy

Time to independent walking

3 months

3 months

One cell stays unstated instead of carrying an estimate. A number absent from the source has no place here.

How acyclovir and antiviral therapy fit the timeline

Acyclovir has a clear role in the first phase of this story. It treated the acute herpesvirus encephalitis, and the acute illness resolved. The important detail is the step-down schedule in the first case: 2 weeks of intravenous aciclovir followed by 1 week of oral acyclovir. The treating team chose that route because acute symptoms were relatively mild and the viral read count from cerebrospinal fluid sequencing was moderate.

When ataxia appeared 5 to 8 weeks later, viral replication was no longer the clinical problem. Cerebrospinal fluid findings had normalized, imaging was clean, and the new syndrome matched an antibody-associated cerebellar phenotype. The antiviral course was finished; the immune process was just beginning.

This sequence places the cases in post-viral cerebellar ataxia, not in antiviral failure. The drug worked for the infection it was given to treat. It was never expected to prevent a delayed autoimmune response. For a manufacturer of nucleoside analogue active ingredients, the practical distinction is equally clean: acyclovir and related antivirals address viral replication during the acute phase, while the delayed complication described here belongs to immunotherapy and antibody diagnostics. Conflating the two leads to the wrong question at the bedside and the wrong technical claim in a formulation discussion.

The immunotherapy detail that changed the outcome

Both patients received combined intravenous methylprednisolone pulses and intravenous immunoglobulin, followed by a tapering oral corticosteroid. In the first case, the protocol was 5 days of intravenous immunoglobulin at 0.4 grams per kilogram per day and 5 days of intravenous methylprednisolone at 120 milligrams per day. Oral methylprednisolone then started at 48 milligrams daily and was reduced by 4 milligrams each week.

At 1 month gait stability had improved substantially, and by 3 months cerebellar dysfunction had resolved. No treatment-related adverse events appeared during therapy or follow-up. The second patient followed a similar course with the same endpoint. Neither patient had a standardized ataxia rating scale applied prospectively; recovery was assessed by bedside neurological examination. Without prospective scale scores the outcome is less precise, though the functional result stands.

Across the 19 reported anti-neurochondrin ataxia cases, first-line therapy included corticosteroid pulses in 15 cases and intravenous immunoglobulin in 13 cases. Second-line agents included cyclophosphamide in 5 cases, azathioprine in 4, rituximab in 4, mycophenolate mofetil in 2, and plasma exchange in 2. One patient received no immunotherapy. Earlier combined steroid and immunoglobulin treatment was associated with symptom relief within 2 to 4 weeks in some reported patients, while delayed treatment in several historical cases ended in persistent disability or death. Mycophenolate mofetil appears here as one of several second-line immunosuppressants used in this rare antibody-associated syndrome. That is a link in a treatment chain, not a claim that the drug was the study variable or that the new cases received it.

The counterintuitive part

The finding with the most practical value runs against the usual instinct. A patient can complete a successful antiviral course, be discharged as recovered, and then develop a cerebellar syndrome that looks like a new neurological emergency. The instinct is to treat the virus again. The correct move is to test for an antibody.

Three features separate the second illness from the first:

  • The timing is subacute, with a symptom-free interval of 5 to 8 weeks after discharge.
  • The cerebrospinal fluid inflammation has settled, and imaging shows no new structural lesion.
  • Standard cerebellar autoantibody panels are negative while neurochondrin IgG is positive in both serum and cerebrospinal fluid.

One further feature is easy to overlook. The underlying mechanism appears to be cytotoxic T-cell-predominant neuronal injury rather than direct antibody toxicity. That means antibody titer alone may not track disability, and a positive result should be interpreted alongside the clinical phenotype. The authors describe molecular mimicry, bystander immune activation, and epitope spreading as the three frameworks for delayed autoimmunity after herpes simplex, varicella zoster, or Epstein-Barr virus encephalitis. These are plausible mechanisms, not measured findings in the two patients.

The phenotype also surprised the clinical team. Classic anti-neurochondrin disease often combines ataxia with cognitive decline. These two patients had predominantly isolated cerebellar dysfunction without prominent memory impairment. The authors propose differential antigen-epitope targeting as one explanation. The study did not test that idea.

What a clinician or API manufacturer should take from this

A short set of decisions follows from the cases.

  • Add anti-neurochondrin IgG testing when a patient develops new cerebellar signs weeks after viral encephalitis, especially if the routine antibody panel is negative and MRI is normal.
  • Test serum and cerebrospinal fluid in parallel. In both cases the paired samples were positive at the same titer, which strengthened the diagnostic interpretation.
  • Treat a positive result as a reason to discuss immunotherapy promptly. In the reported cases, combined steroid and immunoglobulin therapy preceded recovery of independent walking within 3 months.
  • Keep the antiviral story separate. Acyclovir, valacyclovir, ganciclovir, and valganciclovir act during active viral replication. They are not the intervention for a delayed antibody-mediated cerebellar syndrome.
  • Record functional status with a validated ataxia scale in future cases. The absence of prospective Scale for the Assessment and Rating of Ataxia scoring is a real gap in the current evidence.
  • Do not infer incidence. The cohort was assembled from patients with established autoimmune ataxia, not from all encephalitis survivors.

An active ingredient supplier faces the same boundary in its technical claims. Nucleoside analogues such as acyclovir and ganciclovir are manufactured to control purity, stereochemistry, and impurity profile for their labeled antiviral indication. Their role in this clinical narrative stops at viral clearance. A blog that blurred that line would overstate what the molecules do and would mislead readers who are trying to understand the second phase of illness.

Limitations that constrain the conclusion

This is a two-case report with a descriptive literature comparison, not a controlled study. Several limits deserve emphasis.

  • The center did not screen all patients admitted with herpesvirus encephalitis, so the frequency of post-encephalitis autoimmune ataxia is unknown.
  • Neurological recovery was assessed by bedside examination rather than a prospectively applied validated rating scale.
  • The follow-up is short, and it cannot establish durable cure or relapse rate.
  • The cases show a temporal association. They do not prove that the preceding herpesvirus infection caused the antibody response.
  • Whole-body fluorodeoxyglucose positron emission tomography excluded malignancy in both patients, but the small sample cannot define how often paraneoplastic disease should be expected in this phenotype.
  • The pooled literature group contains 19 reported cases, which is too small for stable treatment comparisons.
  • The proposed mechanisms are drawn from broader post-viral autoimmunity literature and were not directly tested here.

These limits set the boundary of what the observation supports. A clinician can justify an antibody test and early immunotherapy discussion. A manufacturer cannot claim any protective effect of an antiviral against this delayed complication.

Bottom line

Post-viral cerebellar ataxia should enter the differential when a patient returns with subacute gait and limb incoordination 5 to 8 weeks after herpesvirus encephalitis, especially with a normal MRI and a negative routine antibody panel. In the two reported cases, paired serum and cerebrospinal fluid neurochondrin IgG positivity at 1:100 and combined immunotherapy were followed by independent ambulation at 3 months. Acyclovir belongs to the acute antiviral phase. The delayed syndrome belongs to antibody testing and immunomodulation. The evidence is a case series, so the recommendation is to test and treat early, not to assume causation or predict incidence.

FAQ

How soon can post-viral cerebellar ataxia appear after encephalitis?

In the two reported cases the interval was 5 to 8 weeks after discharge from acute herpesvirus encephalitis. The first patient developed dizziness, an unstable gait, slurred speech, and limb incoordination at 6 weeks. This timing fits the description of a delayed post-infectious cerebellar syndrome rather than a relapse of the acute infection, because cerebrospinal fluid inflammation had already settled and imaging showed no new lesion.

What symptoms should prompt testing for anti-neurochondrin IgG?

New gait instability, limb dysmetria, dysarthria, and gaze-evoked nystagmus that progress over days to weeks after an encephalitis recovery should raise the question. The antibody is worth checking when brain MRI shows no cerebellar atrophy or focal lesion and the usual cerebellar autoantibody panel is negative. In the reported patients, serum and cerebrospinal fluid were both positive at a titer of 1:100.

Did acyclovir fail in these patients?

No. The first patient received 2 weeks of intravenous aciclovir followed by 1 week of oral acyclovir, and the acute encephalitis resolved completely by discharge. The later cerebellar syndrome emerged after the virus was controlled and was attributed to an antibody-associated process. Acyclovir treats viral replication; it was never the treatment for the delayed immune complication. Restarting it would not have addressed the new problem.

How were the two patients treated after the ataxia started?

Both received combined intravenous methylprednisolone pulse therapy and intravenous immunoglobulin, followed by a tapering oral corticosteroid. In one protocol, immunoglobulin was given for 5 days at 0.4 grams per kilogram per day and methylprednisolone for 5 days at 120 milligrams per day. Gait improved at 1 month and full resolution of cerebellar dysfunction was recorded at 3 months.

What did the imaging show during the ataxia phase?

Brain MRI showed no cerebellar atrophy, no focal parenchymal lesion, and no meningeal enhancement in either patient. Whole-body fluorodeoxyglucose positron emission tomography with CT was used to look for an underlying malignancy and found none. The absence of structural findings was one reason the team pursued an autoimmune explanation instead of a structural or neoplastic one.

Is anti-neurochondrin IgG a common antibody?

No. Anti-neurochondrin associated primary autoimmune cerebellar ataxia is described as exceedingly rare. The literature comparison found 19 reported cases in total, including the two new ones. Within the 54-patient autoimmune ataxia cohort described here, only two patients had both prior herpesvirus encephalitis and confirmed paired antibody positivity. A negative result on a routine panel does not exclude it, because this antibody is not part of every standard screen.

Which viruses were involved in the two cases?

Metagenomic next-generation sequencing detected human herpesvirus 4 DNA in the first patient and human herpesvirus 6 in the second. Both belong to the herpesvirus family. The discussion places the cases alongside broader literature on delayed autoimmunity after herpes simplex, varicella zoster, and Epstein-Barr virus encephalitis, but the mechanism was not directly demonstrated in these two patients.

Why test cerebrospinal fluid as well as serum?

Paired positivity strengthens the interpretation. Both patients had neurochondrin IgG at 1:100 in serum and cerebrospinal fluid, while other cerebellitis-related antibodies were negative. Tissue-based assay with patient cerebrospinal fluid produced a diffuse granular staining pattern, and cell-based assay confirmed the specificity. Testing only serum could leave the clinician with a weaker and less defensible signal.

What role did mycophenolate mofetil play?

Mycophenolate mofetil appears only as a second-line option in the pooled literature, used in two of 19 reported anti-neurochondrin ataxia cases. It was not the treatment given to the two new patients and it was not the study variable. Its presence in the treatment list shows that immunosuppressive options exist beyond steroids and immunoglobulin, but the case series cannot rank those options.

Can the frequency of this complication be estimated from the study?

No. The cohort was assembled from patients who already met criteria for primary autoimmune cerebellar ataxia. The center did not systematically test all patients admitted with herpesvirus encephalitis. Without that denominator, no incidence or risk percentage can be calculated. The article reports a clinical pattern and a diagnostic pathway, not an epidemiological rate.

What should be improved in future studies?

Future work should apply a validated ataxia rating scale prospectively, enroll a defined denominator of encephalitis survivors, follow patients beyond the acute recovery window, and collect paired blood and tissue samples at standardized time points. Those changes would turn a compelling case pattern into a testable risk model and would clarify whether antibody titer tracks functional outcome.